Medication Juno-B (02126): Benodat® (rekiolense injection) included in the national basic medical insurance drug catalogue

Zhitongcaijing · 1d ago

Zhitong Finance App News, Pharmaceutical Juno-B (02126) announced that the company's core product Benodat® (Reggiolense Injection) was officially included in the 2026 edition of the National Basic Medical Insurance Drug Catalogue (NRDL). From January 1, 2027, patients who are covered by national health insurance payments can use Benoda® and enjoy basic medical insurance reimbursement according to regulations. This medical insurance payment covers the three approved indications of Benoda®, including large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The price of Benoda® included in the national basic medical insurance catalogue is RMB 288,600.

As the only chimeric antigen receptor T cell (CAR-T) therapy product included in the national basic medical insurance drug catalogue, Benoda® will further lower the payment threshold for eligible patients to receive CAR-T treatment and promote this cutting-edge innovative therapy to benefit more patients. As payment guarantees are further improved, CAR-T treatment is expected to be more widely incorporated into clinical diagnosis and treatment decisions, promoting timely identification, referral and evaluation of potential beneficiaries. Clinicians can comprehensively evaluate treatment options and timing of intervention based on patients' disease progression, previous treatment conditions and individualized needs, and formulate more reasonable treatment plans for eligible patients.